2006•PubMedRequires access

[Lysophosphatidic acid in ovarian cancer patients].

Iva Sedláková, J Vávrová, J Tošner, Ladislav Hanousek

Abstract

OBJECTIVE: To compare plasma lysophosphatidic acid (LPA) level in ovarian cancer patients and women without ovarian pathology. DESIGN: Prospective study. SETTING: Department of Gynecology and Obstetrics, University Hospital, Hradec Králové. METHODS: The method for LPA level analyze with its specification by capillary electrophoresis using indirect ultraviolet detection has been implementated. Since the beginning of this project venous blood samples from 103 patients (60 patients with ovarian cancer, 43 patients without ovarian pathology) have been obtained. RESULTS: Plasma LPA levels were elevated in ovarian cancer patients (sigma LPA Med 19.9 micromol/l, Range 4.5-42.7 micromol/l). Patients without ovarian pathology (n=35) (sigma LPA Med 2.6 micromol/l, Range 0.9-22.9 micromol/l, P<0,001) had statistically significant lower plasma LPA level compared with ovarian cancer patients. CONCLUSION: Lysophosphatidic acid appears useful as diagnostic marker of ovarian cancer.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 14 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Lysophosphatidic acid, Ovarian cancer, Medicine, Venous blood, Internal medicine, Gastroenterology, Prospective cohort study, Obstetrics and gynaecology